- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Repurposed ebselen shows promise in bipolar trial
9 December 2015 • Author: Victoria White
A team of scientists from the University of Oxford may have found a new role for a drug that was destined for the scrap heap, ebselen, in treating bipolar disorder.
The team used a database of ‘failed’ drugs, found to be safe but ineffective for their proposed use, to identify ebselen as a possible alternative to lithium, the main treatment for people who are bipolar.
Ebselen was under development as a treatment for stroke, but was abandoned in the final phase of clinical trials. However, those trials proved that the drug was safe for use in humans. Initial tests of ebselen as a treatment for bipolar disorder were carried out in mice. That research, reported in early 2014, found that results were promising, so the researchers were able to use the existing safety information to fast track an initial trial of the drug in humans.
Ebselen has similar effects on the brain to lithium
Dr Grant Churchill explained: “Lithium has been used for over 60 years and remains the most effective treatment for bipolar disorder, but suffers from toxicity and has many side effects. It is toxic at only twice the right dose and can cause weight gain and thirst. Long-term lithium use can lead to kidney damage. The side effects also encourage people to stop taking it, which means they can relapse.
“An alternative treatment that has fewer side effects would be safer and would likely have a lower rate of people stopping taking their prescribed drug. Lower toxicity also means fewer medical appointments to get the dose right and fewer visits to monitor for side effects.”
In a small trial, healthy adult volunteers were given a course of ebselen. They carried out a number of tests of brain function, provided blood samples and also went through an MRI scan .
The results showed that ebselen had similar effects on the brain to lithium. The next stage will be a full clinical trial to test the effectiveness of ebselen as a treatment. The researchers have obtained funding from the Stanley Medical Research Institute in the United States to conduct a ‘proof of concept’ study for ebselen in patients with bipolar disorder. It is hoped that the study will start in 2016.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics